Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

Multiplyme7x Apr. 25 at 12:28 PM

$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .

0 · Reply

KY3000 Apr. 24 at 2:37 PM

$STRO is caked up, 250$ mill realized, 200$ mill TD raise(done?)projected 350$ mill milestones next 2years if you believe in vaxcyte/astellas.

0 · Reply

erevnon Apr. 23 at 3:22 PM

Citizens maintains Sutro Biopharma $STRO at Market Outperform and raises the price target from $35 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

KY3000 Apr. 22 at 4:21 PM

$STRO Pfizer, astra, exelixis are watching

1 · Reply

KY3000 Apr. 22 at 4:09 PM

$STRO sciencetific posters are out. Still sticking by preclinical safety on 004. Hers2 dpADC NHP study done, this next?, they have data to compare with, enherta

0 · Reply

ibaian Apr. 21 at 2:35 AM

$STRO Told you

0 · Reply

Send_IT_or_stepaside Apr. 21 at 12:18 AM

$STRO traded this one under $5 for a while, should have kept it good run. Instead I am stuck in a dead horse $AUPH maybe one day

0 · Reply

KY3000 Apr. 20 at 11:07 PM

$STRO 004,006,227, plus option share US rights with Astellas. $ coming

0 · Reply

KY3000 Apr. 20 at 4:58 PM

$STRO this is their preclinical

1 · Reply

JosephLinke Apr. 20 at 1:54 AM

@JosephLinke $STRO Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

0 · Reply

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Mar 10, 2026, 1:05 PM EDT - 6 weeks ago

Sutro Biopharma Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 1:50 PM EST - 7 weeks ago

Sutro Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:30 AM EST - 2 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 2 months ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Jan 15, 2026, 2:15 PM EST - 3 months ago

Sutro Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 3:30 PM EST - 5 months ago

Sutro Biopharma Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 5 months ago

Sutro Biopharma Transcript: R&D Day 2025

Nov 6, 2025, 4:30 PM EST - 6 months ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 4:05 PM EST - 6 months ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Nov 3, 2025, 8:00 AM EST - 6 months ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sep 29, 2025, 5:05 PM EDT - 7 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sep 3, 2025, 2:15 PM EDT - 8 months ago

Sutro Biopharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Jun 4, 2025, 11:05 AM EDT - 11 months ago

Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 11:00 AM EDT - 11 months ago

Sutro Biopharma Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 13, 2025, 7:35 PM EDT - 1 year ago

Sutro Biopharma Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:31 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Mar 15, 2025, 6:40 PM EDT - 1 year ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 14, 2025, 12:09 PM EDT - 1 year ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Earnings Call Transcript: Q4 2024

Mar 4, 2025, 2:30 PM EST - 1 year ago

Sutro Biopharma Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 15, 2025, 5:15 PM EST - 1 year ago

Sutro Biopharma Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 4:00 PM EST - 1 year ago

Sutro Biopharma Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 2:30 PM EST - 1 year ago

Sutro Biopharma Transcript: JMP Hematology and Oncology Summit 2024

Nov 21, 2024, 7:30 AM EST - 1 year ago

Sutro Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Transcript: Status Update

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sep 5, 2024, 3:00 PM EDT - 1 year ago

Sutro Biopharma Transcript: 2024 Wells Fargo Healthcare Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 3, 2024, 10:00 AM EDT - 2 years ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 13, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 2, 2024, 6:18 AM EDT - 2 years ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 2 years ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:30 PM EST - 2 years ago

Sutro Biopharma Transcript: Study Update

Jan 4, 2024, 4:05 PM EST - 2 years ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$

Dec 11, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 21, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Transcript: Citi 18th Annual BioPharma Conference

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 3, 2023, 4:00 PM EDT - 3 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 8, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Apr 27, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023, 1:30 PM EDT - 3 years ago

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 17, 2023, 4:01 PM EDT - 3 years ago

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2023, 2:15 PM EST - 3 years ago

Sutro Biopharma Transcript: 41st Annual J.P. Morgan Healthcare Conference

Jan 9, 2023, 4:30 PM EST - 3 years ago

Sutro Biopharma Transcript: Status Update

Nov 9, 2022, 11:35 AM EST - 3 years ago

Sutro Biopharma Transcript: Credit Suisse 31st Annual Healthcare Conference

Sep 9, 2022, 10:25 AM EDT - 3 years ago

Sutro Biopharma Transcript: 2022 Wells Fargo Healthcare Conference

Aug 10, 2022, 2:20 PM EDT - 4 years ago

Sutro Biopharma Transcript: 13th Annual Wedbush PacGrow Healthcare Conference 2022

Jul 20, 2022, 4:30 PM EDT - 4 years ago

Sutro Biopharma Transcript: Study Update

Jan 13, 2022, 11:15 AM EST - 4 years ago

Sutro Biopharma Transcript: JPMorgan 40th Annual Healthcare Conference

Jan 5, 2022, 5:00 PM EST - 4 years ago

Sutro Biopharma Transcript: Study Result

Nov 10, 2021, 4:20 PM EST - 4 years ago

Sutro Biopharma Transcript: 30th Annual Credit Suisse Healthcare Conference

Jun 3, 2021, 1:00 PM EDT - 5 years ago

Sutro Biopharma Transcript: AGM 2021

Jan 14, 2021, 5:20 PM EST - 5 years ago

Sutro Biopharma Transcript: 39th Annual JPMorgan Virtual Healthcare Conference

Multiplyme7x Apr. 25 at 12:28 PM

0 · Reply

KY3000 Apr. 24 at 2:37 PM

$STRO is caked up, 250$ mill realized, 200$ mill TD raise(done?)projected 350$ mill milestones next 2years if you believe in vaxcyte/astellas.

0 · Reply

erevnon Apr. 23 at 3:22 PM

Citizens maintains Sutro Biopharma $STRO at Market Outperform and raises the price target from $35 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

KY3000 Apr. 22 at 4:21 PM

$STRO Pfizer, astra, exelixis are watching

1 · Reply

KY3000 Apr. 22 at 4:09 PM

$STRO sciencetific posters are out. Still sticking by preclinical safety on 004. Hers2 dpADC NHP study done, this next?, they have data to compare with, enherta

0 · Reply

ibaian Apr. 21 at 2:35 AM

$STRO Told you

0 · Reply

Send_IT_or_stepaside Apr. 21 at 12:18 AM

$STRO traded this one under $5 for a while, should have kept it good run. Instead I am stuck in a dead horse $AUPH maybe one day

0 · Reply

KY3000 Apr. 20 at 11:07 PM

$STRO 004,006,227, plus option share US rights with Astellas. $ coming

0 · Reply

KY3000 Apr. 20 at 4:58 PM

$STRO this is their preclinical

1 · Reply

JosephLinke Apr. 20 at 1:54 AM

@JosephLinke $STRO Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

0 · Reply

KY3000 Apr. 19 at 2:12 PM

$STRO presentations all week starting today. Their 1 partner/data point away from 100$ a share

2 · Reply

ibaian Apr. 18 at 4:16 PM

$STRO told you guys

0 · Reply

Zaksab Apr. 18 at 3:53 PM

$STRO only 1k followers here. That’s always a good sign.

0 · Reply

KY3000 Apr. 17 at 3:39 PM

$STRO 👊

0 · Reply

KY3000 Apr. 17 at 2:22 PM

$STRO I’m in luv with Jane, I’ll fight you for her

0 · Reply

G101SPM Apr. 16 at 6:50 PM

$STRO $29.65 bid. SELL/TAKE PROFIT on 50% of net long . DAC (dollar average cost includes BUY$ to enhance long position). Change EXIT to $35.00 (long term) https://stocktwits.com/G101SPM/message/548878533

0 · Reply

KY3000 Apr. 15 at 2:02 PM

$STRO how do you evaluate this? Astellas milestone s worth 840$ mill, vaxcyte blackstone 240$ mill, 440$ mill cash, pipeline?

2 · Reply

KY3000 Apr. 15 at 12:58 PM

$STRO I think 1.5$ bill market cap doable

1 · Reply

Zaksab Apr. 14 at 9:31 PM

$STRO looks like the move could be due to Lilly buying early stage dual payload ADC company Crossbridge Bio

1 · Reply

TrustButVerifi Apr. 14 at 8:15 PM

$STRO Is there a leak here?

1 · Reply

TrustButVerifi Apr. 14 at 8:05 PM

$STRO what just happened?

0 · Reply

KY3000 Apr. 14 at 2:47 PM

$STRO crazy moves today

1 · Reply

Market Cap	552.21M
Revenue (ttm)	102.48M
Net Income (ttm)	-191.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-186.47%
Debt to Equity Ratio	0.00

Volume	344,400
Avg Vol	202,080
Day's Range	N/A - N/A
Shares Out	16.57M
Stochastic %K	75%
Beta	1.31
Analysts	Strong Sell
Price Target	$32.11